Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 101 OP06-07 | DOI: 10.1530/endoabs.101.OP-06-07

1 ONKOS Molecular Diagnostics; 2 Barretos Cancer Hospital; 3 Botucatu Medical School, São Paulo State University (Unesp); 4 Rede D’Or Hospitals Network; 5 State University of Ponta Grossa (UEPG); 6 Erasto Gaertner Hospital; 7 Integrated Center for Head and Neck Surgery (NICAP); 8 The Portuguese Beneficence of São Paulo (BP); 9 Surgical Cancerology, Complexo ISPON; 10 Midwestern State University (UNICENTRO); 11 Peruvian University Cayetano Heredia; 12 Santa Casa de São Paulo School of Medical Sciences; 13 São Paulo Federal University (Unifesp/EPM); 14 Ribeirão Preto Medical School, University of São Paulo (USP/RP); 15 Dr. Cesar Milstein Hospital; 16 Institute of Biomedical Sciences, University of São Paulo (USP)


Background: Thyroid nodules are present in nearly 60% of the population, representing the most frequent endocrine disease. Fine-needle aspiration (FNA) cytopathology classifies 20%–30% of nodules as indeterminate (Bethesda 3 and 4), a scenario in which molecular tests are recommended aiming to avoid unnecessary diagnostic surgeries.

Objective: The aim was to evaluate the diagnostic performance of the new v2 algorithm of mir-THYpe full molecular classifier test for preoperative diagnosis of cytologically indeterminate thyroid nodules, optimized by the use of new machine learning techniques, larger sample cohort size, multicentricity and association of DNA-mutation analysis.

Methods: A multicenter validation study was conducted on a set of 2.372 thyroid nodules with Bethesda 3 and 4 cytology from 15 academic, community and private centers in Brazil, Argentina and Peru. Eligibility criteria were met in 510 nodules. The FNA smear slides were used to obtain and analyze microRNA expression and DNA mutations (BRAF V600E and pTERT C228/250T) by qPCR. Molecular data from 306 (150 benign/156 cancer+NIFTP) nodules were used to retrain and optimize the mir-THYpe v2 algorithm, using random forest, SVM and neural networks machine learning techniques. For final validation, molecular data from 204 (151 benign/53 cancer+NIFTP) thyroid nodules were used to measure diagnostic performance. Anatomopathological data were used as gold-standard for blinded comparison.

Results: In the validation set, 61.8% of the samples were assigned as Bethesda 3 (126) and 38.2% as Bethesda 4 (78). The v2 algorithm had a specificity of 94% (95% Cl, 84-99), a sensitivity of 89% (95% Cl, 83-94) and an accuracy of 91% (95% Cl,86-94). At 26% cancer prevalence, the negative predictive value was 98% (95% Cl, 94-99) and the positive predictive value was 76% (95% Cl, 66-83) with a benign call rate of 68% (138/204). The v2 algorithm was able not only to classify but also to identify as medullary thyroid carcinoma (MTC) in all the MTC samples (5/5).

Conclusion: The optimized classifier demonstrated a high diagnostic performance for identifying benign nodules, which may potentially obviate diagnostic surgery in 68% of patients with indeterminate nodules, and up to 89% of all benign nodules cytologically indeterminate. The BRAF and pTERT status analysis, added to the ability to rule-in cancer samples may help to guide prognostic decisions, including surgery extension and individualized treatments.

Volume 101

46th Annual Meeting of the European Thyroid Association (ETA) 2024

European Thyroid Association 

Browse other volumes

Article tools

My recent searches

No recent searches.

Authors